Lantheus控股 LNTH 深 沪
已收盘 12-12 16:00:00 美东时间
66.62
+3.520
+5.58%
华盛通- 最 高67.35
- 今 开64.415
- 成交量 155.00万股
- 最 低 64.415
- 昨 收 63.10
- 总市值 45.30亿
- 52周最高 111.29
- 市盈率 静 15.28
- 换手率 2.28%
- 52周最低 47.25
- 委 比 -98.44%
- 总股本 6799.41万
- 历史最高 126.8899
- 量 比 1.45
- 振 幅 4.65%
- 历史最低 1.76
- 每 手 1
- 风险率 18.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Truist Securities Upgrades Lantheus Holdings to Buy, Raises Price Target to $80
Truist Securities analyst Richard Newitter upgrades Lantheus Holdings (NASDAQ:LNTH) from Hold to Buy and raises the price target from $61 to $80.
12-12 22:44
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
Molecular Partners AG, a clinical-stage biotech company, has announced the formation of a Scientific Advisory Board (SAB) for its radiopharmaceuticals, led by Prof. Ken Herrmann, a renowned nuclear medicine expert. The board includes industry leaders James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D., aiming to guide the company's transition from early clinical validation to strategic development. The SAB will focus on refining scientific a...
12-11 12:00
Lantheus to Present Florbetaben F 18 Data at CTAD 2025
Lantheus Holdings, Inc. announced the presentation of new florbetaben F18 data at the CTAD 2025 conference in San Diego. The poster presentation, titled "Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab," will be displayed on December 3. Neuraceq (florbetaben F 18 injection) is used for PET imaging to estimate amyloid beta plaque density in adults with cognitive impairment. Important saf...
11-24 13:30
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
Lantheus Holdings Narrows FY2025 Adj EPS Guidance from $5.50-$5.70 to $5.50-$5.65 vs $5.63 Est; Raises FY2025 Sales Guidance from $1.475B-$1.510B to $1.490B-$1.510B vs $1.483B Est
Lantheus Holdings (NASDAQ:LNTH) narrows FY2025 Adj EPS guidance from $5.50-$5.70 to $5.50-$5.65 vs $5.63 analyst estimate. Raises FY2025 sales outlook from $1.475 billion-$1.510 billion to $1.490 billion-$1.510 billion
11-06 20:19
Lantheus CEO Brian Markison To Retire, Effective Dec. 31; Mary Anne Heino Appointed Executive Chairperson, Interim CEO, Effective Nov. 7; President Paul Blanchfield Departing
Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today
11-06 20:19
Lantheus Holdings Q3 Adj. EPS $1.27 Beats $1.26 Estimate, Sales $384.014M Beat $363.365M Estimate
Lantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.26 by 0.47 percent. This is a 25.29 percent decrease over earnings of $1.70 per share from
11-06 20:18
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Lantheus Announces Leadership Transition Plan
Lantheus Holdings, Inc. announces that CEO Brian Markison will retire on December 31, 2025, after 13 years of service. The board has started a search for a new CEO, with Markison staying on as a strategic advisor until March 2026. Mary Anne Heino, former CEO, will serve as Executive Chairperson and interim CEO until a permanent replacement is found. Paul Blanchfield, the company's President, is leaving to join another firm, and Amanda Morgan will...
11-06 12:00
Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
The FDA has accepted Lantheus' NDA for MK-6240, an F18-labeled PET imaging agent targeting tau neurofibrillary tangles in Alzheimer's disease. The PDUFA target action date is August 13, 2026. MK-6240 previously received Fast Track designation and has shown promise in detecting tau pathology, with pivotal Phase 3 trials meeting sensitivity and specificity endpoints. Lantheus highlights the potential of MK-6240 to address unmet diagnostic needs in ...
10-28 12:30
